Compare THM & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THM | CABA |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.5M | 495.7M |
| IPO Year | 2002 | 2019 |
| Metric | THM | CABA |
|---|---|---|
| Price | $2.32 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 1.1M | ★ 5.4M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $207.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $1.26 |
| 52 Week High | $3.65 | $4.23 |
| Indicator | THM | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 48.87 |
| Support Level | $2.19 | $3.12 |
| Resistance Level | $2.80 | $3.34 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 92.24 | 69.61 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.